Speak to your health provider about GLP-1 options
The medication is a single molecule that targets both incretin receptors, GLP-1r and GIPr
It is not scheduled under the Controlled Drugs and Substances Act but remains an unapproved compound with significant risks
Whether the drug makers will agree to it or not is a question of, do you want your product to be marketed in Pennsylvania to the Medicaid population or not? Venkat said
We combine medication with nutritional guidance, physical activity, and behavioral support to maximize and sustain results
However, the longer-term impact of GLP-1RAs is likely to be positive for the industry, driven by an expected higher uptake of physical activity by previously overweight individuals, and the growing evidence of the importance of exercise to preserving muscle mass